Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many ...

Pfizer Inc Chief Executive Officer Albert Bourla sold $5.56 million worth of company shares on Monday, the day the drugmaker said its COVID-19 vaccine was 90% effective based on interim trial results, ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S.

Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, ...

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple ...

From Elon Musk and Satya Nadella to the co-founder of Moderna, it’s not just tycoons in Silicon Valley who have benefited ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as ...

Get this week's top healthcare stock movers, market trends, and exclusive updates on key pharma deals and drug pricing.

AstraZeneca on Friday became the second big drugmaker after Pfizer to cut a pricing deal with the White House, announcing an ...